The Ras guanine nucleotide exchange factor RasGRF1 promotes matrix metalloproteinase-3 production in rheumatoid arthritis synovial tissue.
BACKGROUND
Fibroblast-like synoviocytes (FLS) from rheumatoid arthritis (RA) patients share many similarities with transformed cancer cells, including spontaneous production of matrix metalloproteinases (MMPs). Altered or chronic activation of proto-oncogenic Ras family GTPases is thought to contribute to inflammation and joint destruction in RA, and abrogation of Ras family signaling is therapeutic in animal models of RA. Recently, expression and post-translational modification of Ras guanine nucleotide releasing factor 1 (RasGRF1) was found to contribute to spontaneous MMP production in melanoma cancer cells. Here, we examine the potential relationship between RasGRF1 expression and MMP production in RA, reactive arthritis, and inflammatory osteoarthritis synovial tissue and FLS.


METHODS
Expression of RasGRF1, MMP-1, MMP-3, and IL-6 was detected in synovial tissue by immunohistochemistry and stained sections were evaluated by digital image analysis. Expression of RasGRF1 in FLS and synovial tissue was also assessed by immunoblotting. Double staining was performed to detect proteins in specific cell populations, and cells producing MMP-1 and MMP-3. RasGRF1 expression was manipulated in RA FLS by cDNA transfection and gene silencing, and effects on MMP-1, TIMP-1, MMP-3, IL-6, and IL-8 production measured by ELISA.


RESULTS
Expression of RasGRF1 was significantly enhanced in RA synovial tissue, and detected in FLS and synovial macrophages in situ. In cultured FLS and synovial biopsies, RasGRF1 was detected by immunoblotting as a truncated fragment lacking its negative regulatory domain. Production of MMP-1 and MMP-3 in RA but not non-RA synovial tissue positively correlated with expression of RasGRF1 and co-localized in cells expressing RasGRF1. RasGRF1 overexpression in FLS induced production of MMP-3, and RasGRF1 silencing inhibited spontaneous MMP-3 production.


CONCLUSIONS
Enhanced expression and post-translational modification of RasGRF1 contributes to MMP-3 production in RA synovial tissue and the semi-transformed phenotype of RA FLS.
Abreu
Joana R F
JR
Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands. j.r.abreu@amc.uva.nl
de Launay
Daphne
D
Sanders
Marjolein E
ME
Grabiec
Aleksander M
AM
van de Sande
Marleen G
MG
Tak
Paul P
PP
Reedquist
Kris A
KA
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000378:metabolism*; D015153:Blotting, Western; D002478:Cells, Cultured; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005347:Fibroblasts / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D015870:Gene Expression; D005786:Gene Expression Regulation / Q000502:physiology*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007150:Immunohistochemistry; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000096:biosynthesis; D019278:Matrix Metalloproteinase 3 / Q000096:biosynthesis*; D008875:Middle Aged; D013583:Synovial Membrane / Q000378:metabolism*; D014162:Transfection; D020666:ras-GRF1 / Q000235:genetics / Q000378:metabolism*
C513039:RASGRF1 protein, human; D020666:ras-GRF1; D019278:Matrix Metalloproteinase 3; D020781:Matrix Metalloproteinase 1
Arthritis Rheum. 2007 Aug;56(8):2523-34
17665433
Curr Opin Rheumatol. 2004 May;16(3):231-7
15103250
Arthritis Rheum. 1997 Feb;40(2):217-25
9041933
Arthritis Rheum. 2003 Sep;48(9):2682-92
13130489
Ann Rheum Dis. 2008 Apr;67(4):559-62
17720720
Immunity. 2003 Aug;19(2):243-55
12932358
Ann Rheum Dis. 2007 Aug;66(8):1043-51
17223661
J Biol Chem. 1997 Mar 7;272(10):6671-6
9045698
Arthritis Rheum. 2006 Oct;54(10):3135-43
17009234
J Clin Invest. 2001 Jan;107(1):7-11
11134171
J Immunol. 2004 Jul 15;173(2):920-31
15240679
Nat Rev Mol Cell Biol. 2008 Nov;9(11):846-59
18946474
J Rheumatol. 2000 May;27(5):1121-7
10813276
FEBS Lett. 1999 Oct 29;460(2):357-62
10544264
J Immunol. 2004 Jul 15;173(2):1276-83
15240720
Rheumatology (Oxford). 2006 Jun;45(6):669-75
16567358
J Immunol. 2007 Oct 1;179(7):4890-900
17878389
Immunol Today. 2000 Feb;21(2):78-82
10652465
Nat Rev Mol Cell Biol. 2002 May;3(5):339-48
11988768
Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4826-31
10220378
Osteoarthritis Cartilage. 2009 Jan;17(1):124-31
18562219
Mol Cancer Ther. 2007 Mar;6(3):833-43
17363479
Mol Reprod Dev. 1995 Dec;42(4):468-76
8607978
J Clin Invest. 1989 Apr;83(4):1267-76
2784799
J Rheumatol. 1999 Jun;26(6):1219-21
10381032
Arthritis Rheum. 2001 Nov;44(11):2705
11710728
Arthritis Rheum. 2000 Nov;43(11):2501-12
11083274
Oncogene. 1996 Dec 5;13(11):2297-306
8957070
Arthritis Rheum. 2001 Jul;44(7):1555-67
11465707
Rheumatology (Oxford). 2008 Jun;47(6):834-9
18400834
Matrix. 1990 Dec;10(6):349-61
2084514
Arthritis Rheum. 1986 Aug;29(8):1039-49
3741515
Arthritis Rheum. 2004 Sep;50(9):2794-802
15457447
Arthritis Rheum. 2002 Aug;46(8):2034-8
12209505
J Immunol. 2008 Oct 1;181(7):5111-9
18802115
J Biol Chem. 1998 Jan 16;273(3):1782-7
9430727
Sci STKE. 2004 Sep 07;2004(250):RE13
15367757
Mol Pharmacol. 2008 Feb;73(2):587-600
18006645
Br J Rheumatol. 1996 Oct;35(10):933-42
8883430
Annu Rev Cell Dev Biol. 2005;21:247-69
16212495
J Biol Chem. 2009 Apr 24;284(17):10995-9
19091745
Arthritis Rheum. 1988 Mar;31(3):315-24
3358796
Arthritis Res. 2000;2(1):59-64
11219390
Arthritis Rheum. 1995 Oct;38(10):1457-65
7575695
J Biol Chem. 2007 May 18;282(20):14816-26
17389601
Clin Immunol. 2003 Jan;106(1):41-9
12584050
Arthritis Res Ther. 2005;7(4):R862-7
15987488
Cell. 2007 Jun 1;129(5):865-77
17540168
J Biol Chem. 2000 Jun 30;275(26):20020-6
10777492
Coll Relat Res. 1983 Mar;3(2):141-55
6851475
Mol Med. 2007 May-Jun;13(5-6):297-304
17622308
Arthritis Rheum. 2005 Feb;52(2):430-41
15692990